Biocon Biologics and Viatris announce Insulin Glargine Injection will be offered through the Walgreens Prescription Savings Club

Biocon Biologics Ltd., a subsidiary of Biocon Ltd., and Viatris Inc. have confirmed that Insulin Glargine (insulin glargine-yfgn) injection will be offered through the Walgreens Prescription Savings Club, saving members up to 80 percent off the cash price of comparable long-acting insulins purchased at Walgreens.

This decision by Walgreens follows the launch of Insulin Glargine (insulin glargine-yfgn) announced on November 16. Biocon Biologics and Viatris co-developed the product, and together the companies are committed to improving patients' access to sustainable, quality and more affordable healthcare.

Biocon Biologics and Viatris are together committed to ensuring that the interchangeable biosimilar insulin glargine can reach as many patients as possible regardless of financial circumstances, insurance or channel. The collaboration with Walgreens underscores our efforts to improve outcomes and access for patients by meeting the needs of cash-paying patients and partnering with key stakeholders across the country to lower out-of-pocket costs for insulin users.

Shares of Biocon Limited was last trading in BSE at Rs. 366.80 as compared to the previous close of Rs. 376.90. The total number of shares traded during the day was 275005 in over 5378 trades.

The stock hit an intraday high of Rs. 378.00 and intraday low of 364.00. The net turnover during the day was Rs. 101561520.00.

Source : Equity Bulls

Keywords

BioconLimited INE376G01013 BIOCON Biotechnology BioconBiologics Viatris InsulinGlargine Walgreen PrescriptionSavingsClub